Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRP-independent process

被引:72
作者
Benchenane, K
Berezowski, V
Fernández-Monreal, M
Brillault, J
Valable, S
Dehouck, MP
Cecchelli, R
Vivien, D
Touzani, O
Ali, C
机构
[1] Univ Caen, Ctr Cyceron, INSERM Avenir, F-14074 Caen, France
[2] Univ Caen, Ctr Cyceron, CNRS, UMR 6185, F-14032 Caen, France
[3] Univ Artois, Fac Sci Jean Perrin, EA 2465, Lab Physiopathol Barriere Hematoencephal, Arras, France
关键词
blood-brain barrier; stroke; thrombolytic therapy; tissue plasminogen activator;
D O I
10.1161/01.STR.0000163050.39122.4f
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose - Despite uncontroversial benefit from its thrombolytic activity, the documented neurotoxic effect of tissue plasminogen activator (tPA) raises an important issue: the current emergency stroke treatment might not be optimum if exogenous tPA can enter the brain and thus add to the deleterious effects of endogenous tPA within the cerebral parenchyma. Here, we aimed at determining whether vascular tPA crosses the blood - brain barrier (BBB) during cerebral ischemia, and if so, by which mechanism. Methods - First, BBB permeability was assessed in vivo by measuring Evans Blue extravasation following intravenous injection at 0 or 3 hours after middle cerebral artery electrocoagulation in mice. Second, the passage of vascular tPA was investigated in an in vitro model of BBB, subjected or not to oxygen and glucose deprivation (OGD). Results - We first demonstrated that after focal permanent ischemia in mice, the BBB remains impermeable to Evans Blue in the early phase ( relative to the therapeutic window of tPA), whereas at later time points massive Evans Blue extravasation occurs. Then, the passage of tPA during these 2 phases, was investigated in vitro and we show that in control conditions, tPA crosses the intact BBB by a low-density lipoprotein (LDL) receptor-related protein (LRP)-dependent transcytosis, whereas OGD leads to an exacerbation of tPA passage, which switches to a LRP-independent process. Conclusion - We evidence 2 different mechanisms through which vascular tPA can reach the brain parenchyma, depending on the state of the BBB. As discussed, these data show the importance of taking the side effects of blood-derived tPA into account and offer a basis to improve the current thrombolytic strategy.
引用
收藏
页码:1059 / 1064
页数:6
相关论文
共 26 条
[1]   Blood-brain barrier disruption and matrix metalloproteinase-9 expression during, reperfusion injury - Mechanical versus embolic focal ischemia in spontaneously hypertensive rats [J].
Aoki, T ;
Sumii, T ;
Mori, T ;
Wang, XY ;
Lo, EH .
STROKE, 2002, 33 (11) :2711-2717
[2]   MOUSE STRAIN DIFFERENCES IN SUSCEPTIBILITY TO CEREBRAL-ISCHEMIA ARE RELATED TO CEREBRAL VASCULAR ANATOMY [J].
BARONE, FC ;
KNUDSEN, DJ ;
NELSON, AH ;
FEUERSTEIN, GZ ;
WILLETTE, RN .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1993, 13 (04) :683-692
[3]   Equivocal roles of tissue-type plasminogen activator in stroke-induced injury [J].
Benchenane, K ;
López-Atalaya, JP ;
Fernández-Monreal, M ;
Touzani, O ;
Vivien, D .
TRENDS IN NEUROSCIENCES, 2004, 27 (03) :155-160
[4]  
BENCHENANE K, 2005, IN PRESS CIRCULATION
[5]   Intercommunications between brain capillary endothelial cells and glial cells increase the transcellular permeability of the blood brain barrier during ischaemia [J].
Brillault, J ;
Berezowski, V ;
Cecchelli, R ;
Dehouck, MP .
JOURNAL OF NEUROCHEMISTRY, 2002, 83 (04) :807-817
[6]   In vitro model for evaluating drug transport across the blood-brain barrier [J].
Cecchelli, R ;
Dehouck, B ;
Descamps, L ;
Fenart, L ;
Buée-Scherrer, V ;
Duhem, C ;
Lundquist, S ;
Rentfel, M ;
Torpier, G ;
Dehouck, MP .
ADVANCED DRUG DELIVERY REVIEWS, 1999, 36 (2-3) :165-178
[7]   Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin [J].
Chen, ZL ;
Strickland, S .
CELL, 1997, 91 (07) :917-925
[8]   DEVELOPMENT OF NOVEL THROMBOLYTIC AGENTS [J].
COLLEN, D ;
DEBONO, DP ;
LIJNEN, HR ;
PANNEKOEK, H .
JOURNAL OF INTERNAL MEDICINE, 1994, 236 (04) :433-437
[9]   Tenecteplase: A review [J].
Davydov, L ;
Cheng, JWM .
CLINICAL THERAPEUTICS, 2001, 23 (07) :982-997
[10]  
Godfrey KR, 1998, BIOPHARM DRUG DISPOS, V19, P131, DOI 10.1002/(SICI)1099-081X(199803)19:2<131::AID-BDD87>3.0.CO